The 3 South Playroom in CHOP’s Main Building officially reopened after a renovation funded by generous support from Dancing While Cancering, the Maddie Kramer Foundation.

Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition on December 8.

In a recent study, researchers at Children’s Hospital of Philadelphia (CHOP) demonstrated that children treated for brain tumors face persistent social challenges, including limited friendships and reduced peer acceptance, extending into adulthood. The study is the first to link disruptions in white matter connectivity to impaired social functioning in survivors of pediatric brain tumors.

Study identified a drug for potential use in future precision medicine clinical trials

Children’s Hospital of Philadelphia (CHOP) announced that five of its physicians and researchers were among the ninety-eight new members selected to join the American Pediatric Society (APS), one of North America's first and most prestigious academic pediatric organizations.

Yael Mossé, MD, received the William Osler Patient Oriented Research Award, which was established in 1996 to honor Osler, a “Father of Clinical Medicine” who, in the 1800s, revolutionized clinical teaching and patient-oriented research at the Perelman School of Medicine at the University of Pennsylvania.

Made possible with a $4 million grant from the Brazilian Ministry of Health, CHOP cell therapy specialists will offer their expertise and resources to oversee this initiative.

Researchers at Children’s Hospital of Philadelphia (CHOP) have elucidated the significant role that alternative splicing – a process whereby a single gene produces multiple proteins by rearranging its messenger RNA segments in different combinations – plays in resistance to chemotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The study published today in the journal Cancer Research.

This award will help research, validate and implement a new model for sharing and integrating data at a national level.

Evan Weber will use this “high risk, high reward” grant to fund research into improving CAR-T therapies.